•  
     
     
    Type Size
     

    IL-33 Shifts the Balance from Osteoclast to Alternatively Activated Macrophage Differentiation and Protects from TNF-{alpha}-Mediated Bone Loss.

    J Immunol. 2011 Apr 22. [Epub ahead of print]

    These authors demonstrate that administration of Interleukin 33 (IL-33), a new member of the IL-1 family, to mice inhibited cartilage destruction, systemic bone loss, and osteoclast differentiation in a mouse model of inflammatory arthritis.  They conclude that IL-33 is an important bone-protecting cytokine and may be of therapeutic benefit in treating pathologic bone resorption.

    Zaiss MM, Kurowska-Stolarska M, Böhm C, Gary R, Scholtysek C, Stolarski B et al

    J Immunol. 2011 Apr 22. [Epub ahead of print]

    http://www.jimmunol.org/content/early/2011/04/22/jimmunol.1003487.long